Table of Contents

U NITED S TATES

S ECURITIES AND E XCHANGE C OMMISSION

W ASHINGTON , DC 20549

 


FORM 10-Q

 


Quarterly Report Under Section 13 or 15(d)

of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2006

Commission file number 0-15070

 


R EGENE R X B IOPHARMACEUTICALS , I NC .

(Exact name of registrant as specified in its charter)

 


 

Delaware   52-1253406
(State of Incorporation)   (IRS Employer I.D. Number)

3 Bethesda Metro Center

Suite 630

Bethesda, Maryland 20814

(Address of principal executive offices)

Issuer’s telephone number, including area code: (301) 280-1992

 


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x     No   ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer   ¨     Accelerated filer   ¨     Non-accelerated filer   x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   ¨     No   x

40,319,134 shares of RegeneRx Biopharmaceuticals, Inc. Common Stock, par value $.001 per share, were outstanding as of June 30, 2006.

 



Table of Contents

RegeneRx Biopharmaceuticals, Inc.

Form 10-Q

Quarterly Period Ended June 30, 2006

I NDEX

 

           Page No.
Part I.    FINANCIAL INFORMATION   
        Item 1.  

Financial Statements.

  
 

Balance Sheets at June 30, 2006 (unaudited) and December 31, 2005

   3
 

Statements of Operations for the three and six months ended June 30, 2006 and 2005 (unaudited)

   4
 

Statements of Cash Flows for the six months ended June 30, 2006 and 2005 (unaudited)

   5
 

Notes to Financial Statements (unaudited)

   6-8
        Item 2.  

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

   9
        Item 3.  

Quantitative and Qualitative Disclosures About Market Risk.

   14
        Item 4.  

Controls and Procedures.

   14
Part II.    OTHER INFORMATION   
        Item 1.  

Legal Proceedings.

   15
        Item 1A.  

Risk Factors.

   15
        Item 2.  

Unregistered Sales of Equity Securities and Use of Proceeds.

   15
        Item 3.  

Defaults Upon Senior Securities.

   15
        Item 4.  

Submission of Matters to a Vote of Security Holders.

   15
        Item 5.  

Other Information.

   16
        Item 6.  

Exhibits.

   17-18

Signatures

   19

 

2


Table of Contents

P ART I – F INANCIAL I NFORMATION

Item 1. Financial Statements

RegeneRx Biopharmaceuticals, Inc.

Balance Sheets

 

    

June 30,

2006

   

December 31,

2005

 
     (unaudited)        
ASSETS     

Current assets

    

Cash and cash equivalents

   $ 6,229,426     $ 4,896,143  

Short-term investments

     5,004,615       2,679,693  

Due from related party

     1,092       4,592  

Other current assets

     107,151       72,894  
                

Total current assets

     11,342,284       7,653,322  

Fixed assets, net of accumulated depreciation of $31,569 and $22,918

     62,859       54,234  

Other assets

     11,749       17,078  
                

Total assets

   $ 11,416,892     $ 7,724,634  
                
LIABILITIES AND STOCKHOLDERS’ EQUITY     

Current liabilities

    

Accounts payable

   $ 298,347     $ 187,666  

Accrued expenses

     1,523,519       526,461  
                

Total current liabilities

     1,821,866       714,127  
                

Commitments

     —         —    

Stockholders’ equity

    

Preferred stock, $.001 par value per share, 1,000,000 authorized; no shares issued

     —         —    

Common stock, par value $.001 per share, 100,000,000 shares authorized; 40,319,134 and 37,629,024 issued and outstanding

     40,319       37,629  

Additional paid-in capital

     62,277,588       54,936,362  

Accumulated other comprehensive loss

     (381 )     (3,044 )

Accumulated deficit

     (52,722,500 )     (47,960,440 )
                

Total stockholders’ equity

     9,595,026       7,010,507  
                

Total liabilities and stockholders’ equity

   $ 11,416,892     $ 7,724,634  
                

The accompanying notes are an integral part of these financial statements.

 

3


Table of Contents

RegeneRx Biopharmaceuticals, Inc.

Statement of Operations

(Unaudited)

 

    

Three months ended

June 30,

   

Six-months ended

June 30,

 
     2006     2005     2006     2005  

Revenues

   $ —       $ —       $ —       $ —    

Expenses:

        

Research and development

     3,102,328       575,289       4,063,405       1,051,515  

General and administrative

     489,227       437,348       950,041       886,145  
                                

Total expenses

     3,591,555       1,012,637       5,013,446       1,937,660  
                                

Operating loss

     (3,591,555 )     (1,012,637 )     (5,013,446 )     (1,937,660 )
                                

Interest income

     154,398       29,227       251,386       55,887  
                                

Net loss

   $ (3,437,157 )   $ (983,410 )   $ (4,762,060 )   $ (1,881,773 )
                                

Basic and diluted net loss per common share

   $ (0.09 )   $ (0.03 )   $ (0.12 )   $ (0.05 )
                                

Weighted average number of common shares outstanding

     40,267,948       36,189,141       39,194,140       36,054,927  
                                

The accompanying notes are an integral part of these financial statements.

 

4


Table of Contents

RegeneRx Biopharmaceuticals, Inc.

Statements of Cash Flows

(Unaudited)

 

    

Six-months ended

June 30,

 
     2006     2005  

Cash flows from operating activities:

    

Net loss

   $ (4,762,060 )   $ (1,881,773 )

Adjustments to reconcile net loss to net cash used in operating activities:

    

Depreciation and amortization

     8,651       6,489  

Compensation expense for stock options

     389,520       90,511  

Changes in operating assets and liabilities:

    

Other current assets

     (34,257 )     (36,325 )

Due from related party

     3,500       3,393  

Other assets

     5,329       (17,078 )

Accounts payable

     110,681       (250,854 )

Accrued expenses

     997,058       (8,307 )
                

Net cash used in operating activities

     (3,281,578 )     (2,093,944 )
                

Cash flows from investing actvities:

    

Purchase of short-term investments

     (5,580,424 )     —    

Maturities of short-term investments

     3,258,165       —    

Purchase of fixed assets

     (17,276 )     (61,908 )

Increase in patent costs

     —         (137,391 )
                

Net cash used in investing activities

     (2,339,535 )     (199,299 )
                

Cash flows from financing activities:

    

Proceeds from issuance of common stock

     7,283,398       4,616,500  

Preceeds from exercise of warrants

     133,237       4,500  

Proceeds from exercise of options

     —         6,650  

Offering costs

     (462,239 )     (75,893 )
                

Net cash provided by financing activities

     6,954,396       4,551,757  
                

Net increase in cash and cash equivalents

     1,333,283       2,258,514  
                

Cash and cash equivalents:

    

Beginning of period

     4,896,143       2,874,260  
                

End of period

   $ 6,229,426     $ 5,132,774  
                

The accompanying notes are an integral part of these financial statements.

 

5


Table of Contents

RegeneRx Biopharmaceuticals, Inc.

Notes to Financial Statements

For the six-months ended June 30, 2006 and 2005 (Unaudited)

A. O RGANIZATION  & BASIS OF PRESENTATION

RegeneRx Biopharmaceuticals, Inc. (the “Company”, “We”, “Us”, “Our”), is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, the Company is developing Thymosin beta 4 (“Tß4”), in part, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that Tß4 may prove efficacious for multiple indications, therefore the Company is developing Tß4 as a therapeutic platform. The Company holds over fifty world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, cardiac and neurological injuries, and septic shock. RegeneRx is currently sponsoring three Phase II dermal wound healing clinical trials and has additionally targeted cardiac and ophthalmic trials in 2006 as part of its ongoing clinical development program.

The accompanying unaudited financial statements reflect, in the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. These statements have been prepared in accordance with generally accepted accounting principles in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. These interim financial statements should be read in conjunction with the audited financial statements and related notes thereto, which are included in our Annual Report on Form 10-KSB for the year ended December 31, 2005. Similarly, this entire report should be read in conjunction with our Annual Report on Form 10-KSB for a broader understanding of our business and inherent risks.

The accompanying December 31, 2005 financial information was derived from audited financial statements. Operating results for the six-month periods ended June 30, 2006 are not necessarily indicative of the results to be expected for the year ending December 31, 2006 or any other future period.

B. N ET L OSS PER S HARE

Net loss per share is based on the weighted average number of common shares outstanding during the three and six months periods ended June 30, 2006 and June 30, 2005. During these periods, certain securities were not included in the calculation as their effect would be anti-dilutive. Securities that could potentially dilute basic net loss per share in the future, and that were not included in the calculation of diluted net loss per share, are as follows:

 

     June 30,
     2006    2005

Outstanding stock options

   2,655,000    2,470,000

Warrants

   2,355,839    1,566,815
         

Total potential common shares excluded from diluted net loss per share computation

   5,010,839    4,036,815
         

C. S TOCK B ASED C OMPENSATION

On January 1, 2006 we adopted Statement of Financial Accounting Standards No. 123 (revised 2004), “Share-Based Payment” (or “FAS 123R”), which supersedes our previous accounting under APB Opinion No. 25, “Accounting for Stock Issued to Employees” (or “APB 25”). FAS 123R requires the recognition of compensation expense, using a fair-value based method, for cost related to all share-based payments including stock options. FAS 123R requires companies to estimate the fair value of share-based payment

 

6


Table of Contents

awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service periods in our Statements of Operations. We adopted FAS 123R using the modified prospective transition method, which requires that compensation expense be recognized in the financial statements for all awards granted after the date of adoption as well as for existing awards for which the requisite service has not been rendered as of the date of adoption. In accordance with the modified prospective transition method, our financial statements for prior periods have not been restated to reflect the impact of FAS 123R.

Prior to the adoption of FAS 123R, we accounted for stock-based awards to employees using the intrinsic value method in accordance with APB 25 as allowed under FAS No. 123, “Accounting for Stock-Based Compensation” (or “FAS 123”). Under the intrinsic value method, no employee stock-based compensation expense had been recognized in our Statement of Operations for any period prior to our adoption of FAS 123R on January 1, 2006, as the exercise price of the stock options granted to employees equaled the fair market value of the underlying stock at the date of grant.

A summary of compensation expense related to stock options follows:

 

     Three months ended
June 30,
   Six months ended
June 30,
     2006    2005    2006    2005

Employees

   $ 115,277    $ —      $ 224,861    $ —  

Non-employees

     87,621      75,961      164,659      90,511
                           

Total compensation expense

   $ 202,898    $ 75,961    $ 389,520    $ 90,511
                           

Research and development

   $ 74,826    $ 13,602    $ 143,959    $ 19,953

General and administrative

     128,072      62,359      245,561      70,558
                           

Total compensation expense

   $ 202,898    $ 75,961    $ 389,520    $ 90,511
                           

Pro Forma Information for Period Prior to Adoption of FAS 123R

The following pro forma net loss and net loss per share were determined as if we had accounted for employee stock-based compensation for our employee stock plans under the fair value method prescribed by FAS 123.

 

     Three months
ended
June 30, 2005
    Six months
ended
June 30, 2005
 

Pro forma net loss:

    

As reported

   $ (983,410 )   $ (1,881,773 )

Total employee non-cash stock compensation expense determined under fair value based method for all awards

     (107,790 )     (108,849 )
                

Pro forma net loss:

   $ (1,091,200 )   $ (1,990,622 )
                

Net loss per common share:

    

Basic and diluted - as reported

   $ (0.03 )   $ (0.05 )

Basic and diluted - pro forma

   $ (0.03 )   $ (0.06 )

Valuation assumptions

The fair value for each option granted was estimated as the date of grant using the Black-Scholes option-pricing model, assuming no expected dividends. The risk free rate of return was established for each award, based on the date of grant and the expected life of the award. Since our historical data is limited, the expected life was determined in accordance with SAB 107 guidance for “plain vanilla” options. The volatility was determined, based on the historical, closing price of the Company’s publicly-traded stock, as measured for a time period consistent with the expected life of the option. Approximate values of these assumptions follow:

 

     2006     2005  

Dividend yield

   0.0 %   0.0 %

Risk free rate of return

   4.3 - 5.0 %   4.3 %

Expected life in years

   6.0 -6.5     6.0 -6.8  

Volatility

   100 - 333 %   400 - 450 %

Stock Option Activity

The following is a summary of option activity for the six months ended June 30, 2006:

 

           Options outstanding
     Shares
available for
grant
    Number of
shares
   Weighted
average
exercise
price

December 31, 2005

   695,000     2,470,000    $ 1.54

Grants

   (185,000 )   185,000      3.01

Exercises

   —       —        —  

Cancellations

   —       —        —  
             

June 30, 2006

   510,000     2,655,000    $ 1.64
                 

Weighted average estimated fair value of options granted, based on the assumptions in the Black-Scholes valuation model

        $ 2.54
           

Estimated fair value of shares vested, based on the fair value assigned to the shares at the time of grant

        $ 728,828
           

The following table summarizes outstanding and exercisable options at June 30, 2006:

 

     Outstanding options    Exerciseable options

Range of exercise prices

   Number of
shares
outstanding
   Weighted-
average
remaining
contractual
life (in years)
   Weighted-
average
exercise
price
   Number of
shares
outstanding
   Weighted-
average
remaining
contractual
life (in years)
   Weighted-
average
exercise
price

$0.28 - $0.86

     1,290,000    5.7    $ 0.38      1,196,250    5.6    $ 0.35

$1.07 - $1.54

     255,000    7.9    $ 1.46      164,866    7.8    $ 1.44

$2.59 - $3.21

     1,110,000    8.9    $ 3.15      191,400    8.8    $ 3.19
                         
     2,655,000            1,552,516      
                         

Intrinsic value of in-the-money options, using the June 30, 2006 closing price of $2.75

   $ 3,388,850          $ 3,092,250      
                         

 

7


Table of Contents

D. O THER C OMPREHENSIVE I NCOME

Our other comprehensive income or loss is comprised solely of unrealized gains and losses on our portfolio of available-for-sale, marketable securities. Annually, we present other comprehensive income or loss in our Statement of Stockholders Equity, and in a footnote during interim periods. For the six months period ended June 30, 2006 we recognized an unrealized gain of $2,663, which reduced our accumulated other comprehensive loss from $3,044 at December 31, 2005 to $381 at June 30, 2006. We did not recognize other comprehensive income or loss in the corresponding interim period in 2005, as we did not maintain an available-for-sale portfolio of marketable securities at that time.

E. E QUITY T RANSACTIONS

Sale of Common Stock and Issuance of Warrants

On March 16, 2006 we sold 2,591,952 shares of common stock for $7,283,398 ($2.81 per share). Included in the sale were warrants to purchase an additional 907,182 shares of common stock at $4.06 per share. These warrants are exercisable from September 16, 2006 to March 16, 2011.

Exercise of Warrants

The following table summarizes outstanding and exercisable warrants at June 30, 2006:

 

          Warrants outstanding
     Number of
shares
   Exercise price
range
   Weighted
average
exercise
price

December 31, 2005

   1,546,815    $ 0.10 - $4.06    $ 1.80

Grants

   907,182      4.06      4.06

Exercises

   98,158      0.10 - 1.50      1.36

Cancellations

   —        —        —  
          

June 30, 2006

   2,355,839    $ 0.10 - $4.06    $ 2.69
          

Subsequent to June 30, 2006 and prior to their expiration on July 23, 2006, we received $641,013 for 427,342 warrants and 48,685 warrants were cancelled, leaving 1,879,812 warrants outstanding, having a weighted average exercise price of $2.99.

 

8


Table of Contents

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This report contains forward-looking statements concerning matters that involve risks and uncertainties. Statements made in this Item that are not purely historical, including statements about us, our respective clinical trials, research programs, product pipelines, current and potential corporate partnerships, licenses and intellectual property, the adequacy of capital reserves and anticipated operating results and cash expenditures, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and Section 27A of the Securities Act of 1933, as amended. Words such as “believes,” “likely,” “may,” and “plans” are intended to identify forward–looking statements, although not all forward-looking statements contain these words. These forward-looking statements concern matters that involve risks and uncertainties that could cause actual results to differ materially from those projected, including risks associated with the success of research and product development programs, the issuance and validity of patents, the development and protection of proprietary technologies, the ability to raise capital, operating expense levels and the ability to establish and retain corporate partnerships, our history of operating losses and the risks set forth under Part II, Item 1A., “Risk Factors.” We do not undertake any obligation to update forward-looking statements. The following should be read in conjunction with our financial statements included in Item 1, and the financial statements in our Annual Report on Form 10-KSB for the year ended December 31, 2005 and in other documents filed by us from time to time with the Securities and Exchange Commission.

Overview

RegeneRx is a biopharmaceutical company focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, we are developing Thymosin beta 4 (“Tß4”), in part, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that Tß4 may prove efficacious for multiple indications. We are, therefore, developing Tß4 as a therapeutic platform. We hold over fifty world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, cardiac and neurological injuries, and septic shock. We are currently sponsoring, in parallel, three Phase II dermal wound healing clinical trials that we believe will be completed by the first quarter of 2007, depending on patient accrual rates. Under our IND, Sigma-Tau is conducting one of these Phase II clinical trials in the EU and will assume all associated costs. Additionally, we have commenced pre-clinical studies targeted at cardiac and ophthalmic indications and expect to submit INDs to the U. S. Food and Drug Administration (“FDA”) for the initiation of clinical trials for these indications during 2006.

We have incurred significant losses since our inception. As of June 30, 2006 our accumulated deficit was $52.7 million. We have incurred net losses due to expenditures for research and development, clinical trials, contract manufacturing, and general and administrative services in support of our operations. We anticipate incurring net losses over at least the next several years as we continue our clinical trials, apply for regulatory approvals, develop our technology, and expand our operations to support the commercialization or out-licensing of our drug candidates.

We also anticipate incurring additional losses for several years as we expand our drug discovery and development programs. We expect that losses will fluctuate from quarter to quarter and that such fluctuations may be substantial. We do not expect to generate revenues from our drug discovery and development efforts for several years, if at all. If we are unable to successfully develop and market pharmaceutical products over the next several years, our business, financial condition and results of operations would be adversely impacted.

 

9


Table of Contents

In July 2005, the first European patent related to Tß4 wound healing technology, licensed from the National Institutes of Health in Bethesda, Maryland, was granted to the Company. The original patent application, filed in 1999, claims numerous compositions, uses and processes related to Tß4. The grant of the European Patent is being opposed by a third party in a proceeding at the European Patent Office, and we cannot guarantee that any or all of the granted claims will prevail. Other such patents have been allowed or issued in China, Hong Kong, Australia and Mexico. Similar patent applications have been submitted in other territories throughout the world, including the U.S. and Asia. We have independently filed over fifty additional world-wide patent applications related to the technology platform.

We utilize an out-sourcing business strategy that we believe is cost effective and allows us the flexibility to implement or modify projects as needed. This strategy employs contract research and development organizations (“CROs”), which have established workforces and facilities to manufacture and formulate our products, as well as conduct clinical trials and perform other product development activities. It also allows us to spend significantly less capital for infrastructure and other fixed costs, all of which we believe maximize shareholder value. We will, therefore, continue to operate our out-sourcing strategy in the near term.

Critical Accounting Policies

Share-based payment – Effective January 1, 2006, we adopted the fair value recognition provisions of FASB Statement No. 123R, using the modified prospective transition method, and therefore have not restated results for prior periods. Under this method we recognize compensation expense for all share-based payments granted to employees after January 1, 2006 and prior to but not yet vested as of January 1, 2006, in accordance with Statement No. 123R. Under the fair value recognition provisions of Statement No. 123R, we recognize stock-based compensation net of an estimated forfeiture rate and only recognize compensation cost for those shares expected to vest on a straight-line basis over the requisite service period of the award. Prior to Statement No. 123R adoption, we accounted for share-based payments to employees under Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees (“APB 25”) and accordingly, generally recognized compensation expense only when we granted options with a discounted exercise price.

Determining the appropriate fair value model and calculating the fair value of share-based payment awards require the input of highly subjective assumptions, including the expected life of the share-based payment awards and stock price volatility. Since our historical data is limited, the expected life was determined in accordance with SAB 107 guidance for “plain vanilla” options. Since our historical trading volume is relatively low, we estimated the expected volatility based on monthly closing prices for a period consistent with the expected life of the option. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our stock-based compensation expense could be materially different in the future. In addition, we are required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. If our actual forfeiture rate is materially different from our estimate, the stock-based compensation expense could be significantly different from what we have recorded in the current period. See Note C to the Financial Statements for a further discussion on stock-based compensation.

Clinical trial costs – We accrue estimated costs for clinical studies conducted by contract research organizations and participating hospitals. These costs are a significant component of research and

 

10


Table of Contents

development expenses. We accrue costs for clinical studies performed by contract research organizations based on estimates of work performed under the contracts. Costs of setting up hospital sites for participation in trials are accrued immediately. Hospital costs related to patient enrollment are accrued as patients are entered in the trial.

Results of operations for the three and six months ended June 30, 2006 and 2005

Research and development expenses

Research and development expenses were $3.10 million for the three months ended June 30, 2006, compared to $0.58 million for the corresponding period in 2005. $1.54 million of the $2.52 million increase was due to our purchase of a significant amount of Tß4, which we purchase in bulk periodically. This particular purchase was to satisfy the drug formulation needs of our expanded clinical development program into ophthalmic and cardiac indications, and for other research use. The remaining increase of approximately $1.0 million is related to the commencement of our three Phase II clinical trials, compared to more limited activities that were associated with Phase I trials and Phase II preparatory work in the second quarter of 2005. Additionally, our clinical development efforts in the cardiac and ophthalmic areas require expanded drug formulation development and pre-clinical trials, none of which had commenced in the second quarter of 2005. Research and development is comprised of all internal and external costs to support our clinical programs, including: drug manufacture, formulation, and stability; fees to clinical trial sites; and, other outside services such as clinical program management.

For the six months ended June 30, 2006, our research and development expenses were $4.06 million compared to $1.05 million for the corresponding period in 2005. Half of the $3.01 million increase related to the Tß4 purchase mentioned previously, with the remaining increase related to the expanded clinical development efforts also previously mentioned.

General and administrative expenses

General and administrative expenses increased by $0.05 million (12%) to $0.49 million for the three months ended June 30, 2006, compared to $0.44 million for the corresponding period in 2005. While the underlying general and administrative costs remained flat, this increase is solely attributable to the additional expenses of SFAS 123R which increased by $0.06 million in the second quarter of 2006 as compared to 2005. General and Administrative expenses are comprised of the direct and indirect expenses of our Board and executive management team, office facilities, attorneys, outsourced service providers such as accountants, attorneys, investor relations, information systems support, and our registered independent public accounting firm.

For the six months ended June 30, 2006, our general and administrative expenses increased by $0.06 million (7.21%) to $0.95 million compared to $0.89 million for the corresponding period in 2005. This relatively small increase is the net of increased non-cash stock compensation expenses of $0.17 million less $0.11 million in net cost savings incurred by bringing in-house general and administrative services that had previously been outsourced.

Interest income

Interest income was $0.15 million and $0.25 million for the three and six month periods ended June 30, 2006 respectively, compared to $0.03 million and $0.06 million for the respective corresponding periods in 2005. These increases in interest income are due to (1) increases in the average amounts invested, which have resulted from new equity financings, (2) the implementation of an actively-managed investment strategy, and (3) the overall market improvement in investment returns.

 

11


Table of Contents

Liquidity and capital resources

Sources of liquidity

Since inception we have financed our operations through the sale of equity securities. At June 30, 2006 we had $11.23 million in cash, cash equivalents and short-term investments.

Cash used in operating activities for the six months ended June 30, 2006 increased by $1.19 million to $3.28 million as compared with $2.09 million in 2005. This increase falls short of the actual $2.88 million increase in the net loss since many of the expenses for the quarter have been accrued and will be paid for in the third quarter.

Cash used in investing activities for the six months ended June 30, 2006 was $2.34 million compared with $0.20 million in 2005. These differences are threefold. First, in 2005 approximately $0.06 million was expended to furnish our new offices compared to just $0.02 million in 2006. Second, $0.14 million in patent costs were capitalized in 2005 compared to $0 in 2006. Due to the early stage of our technology, all costs associated with our patents are expensed, unless the estimated recoverability of these costs is sufficiently probable in the near term. Finally, in 2006 we operated an actively managed investment portfolio, which was not operational in the first half of 2005. Co-incident with our new equity investment in March of 2006 and integral with our active investment management strategy, we invested a net $2.32 million in securities with maturities greater than 90 days from the date of purchase, or qualifying short-term investments.

Cash provided by financing activities for the six months ended June 30, 2006 was $6.95 million compared to $4.55 million in 2005. Each period has its own unique set of equity financing transactions that are more thoroughly discussed in Note E to the financial statements contained herein, and in our Annual Report on Form 10-KSB for the year ended December 31, 2005.

Although no assurance can be given, we believe that our current cash and investment balances will be sufficient to meet our operating needs into the second quarter of 2007. However, those activities will not be sufficient to bring our drug candidates to market and we therefore believe new capital resources will be required, in the coming months, to continue our independent development efforts. Accordingly, we may entertain the possibility of raising additional capital to preserve our liquidity, depending on a number of conditions, including conditions in the capital markets. We regularly consider the conditions of capital markets, dilution, stockholder value and tax consequences of each type of financing. Certain of the financing options available to us may have negative consequences to stockholders such as dilution. Given the volatile nature of the capital markets, decisions to raise capital may require actions that would impose a negative consequence in order to reduce or minimize a more significant negative consequence to stockholders.

Contractual obligations

Our contractual obligations as of June 30, 2006 consist of an office facility lease and obligations to purchase Tß4, as follows:

 

     Payments due by period:
     Total    Under 1 year    1 -3 years

Operating lease

   $ 107,646    $ 71,412    $ 36,234

Purchase obligations

     13,000      13,000      —  
                    
   $ 120,646    $ 84,412    $ 36,234
                    

 

12


Table of Contents

We also have $2,111,000 in other contractual obligations due within one year and related to our research and development efforts. These obligations, however, are contingent on future events, e.g. the rate of patient accrual in our clinical trials. This amount represents the remaining contractual amounts due under various contracts, although all of these contracts could be cancelled by us, in which case we would only be liable to the vendors for work performed to the date of cancellation.

Off Balance Sheet Arrangements

We have no material off-balance sheet arrangements other than those that are discussed above.

 

13


Table of Contents

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

Our investments in marketable securities, which are composed primarily of investment-grade corporate bonds, U.S. government agency debt securities and mortgage and asset-backed securities, are subject to default, changes in credit rating and changes in market value. These investments are also subject to interest rate risk and will decrease in value if market interest rates increase. As of June 30, 2006, cash, cash equivalents and short-term investments were $11.2 million. Due to the nature of these investments, if market interest rates were to increase immediately and uniformly by 10% from levels as of June 30, 2006, the decline in fair value would not be material.

ITEM 4. Controls and Procedures

As of the end of the period covered by this report, based on an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) each of the chief executive and chief financial officers of the Company has concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in its Exchange Act reports is recorded, processed, summarized and reported within the applicable time periods specified by the SEC’s rules and forms.

There were no significant changes in our internal controls or in any other factors that could significantly affect those controls subsequent to the date of the most recent evaluation of our internal controls, including any corrective actions with regard to any significant deficiencies or material weaknesses.

 

14


Table of Contents

P ART II – O THER I NFORMATION

Item 1. Legal Proceedings

None

Item 1A. Risk Factors

There were no material changes to the Risk Factors disclosed in the Company’s Annual Report on Form 10-KSB for the year ended December 31, 2005.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None

Item 4. Submission of Matters to a Vote of Security Holders

(a) The Company’s annual meeting of stockholders was held on July 26, 2006.

(b) At the annual meeting of stockholders, all of the Company’s directors were elected at said meeting as follows:

 

J.J. Finkelstein   Votes For, 38,254,095   Votes Withheld, 121,620
Allan L. Goldstein   Votes For, 38,255,058   Votes Withheld, 120,657
Richard J. Hindin   Votes For, 38,249,168   Votes Withheld,126,547
Joseph C. McNay   Votes For, 38,334,328   Votes Withheld, 41,387
Mauro Bove   Votes For, 38,334,828   Votes Withheld, 40,887
Dr. L. Thompson Bowles   Votes For, 38,327,103   Votes Withheld, 48,612

As all of the directors of the Company were elected at the annual meeting of stockholders, there are no directors whose term of office as a director continued after the meeting.

(c) The following other matters were voted upon at the meeting, and the following number of affirmative votes and negative votes were cast with respect to each such matter:

The amendment of the Amended and Restated 2000 Stock Option and Incentive Plan increasing the number of shares available under the Plan from 3,200,000 to 4,200,000 was approved. This matter received 28,419,868 affirmative votes, 678,445 negative votes, 36,589 votes abstained and 9,240,813 non-votes.

 

15


Table of Contents

The reappointment by the Company’s Board of Directors of the firm of Reznick Group, P.C. as independent certified public accountants to examine the financial statements and perform the annual audit of the Company for the year ending December 31, 2006 was ratified. This matter received 38,339,771 affirmative votes, 7,392 negative votes, 28,552 votes abstained and 0 non-votes.

Item 5. Other Information

None

 

16


Table of Contents

Item 6. Exhibits

 

Exhibit No.  

Description of Exhibit

 

Reference*

3.1   Restated Certificate of Incorporation of the Company   Exhibit 3.1 to Registration Statement No. 33-9370, Amendment No. 1 (filed November 26, 1986)
3.2   Amendment to Restated Certificate of Incorporation of Company   Exhibit 3.2 to the Company’s Transitional Report on Form 10-K, File No. 0-15070 (filed March 18, 1991)
3.3   Amendment to Restated Certificate of Incorporation of Company   Exhibit 3.3 to the Company’s Form 10-KSB, File No. 0-15070 (filed April 2, 2001)
3.4   Amended and restated Bylaws of Company   Filed herewith
4.1   Form of Stock Certificate   Exhibit 4.1 to Registration Statement No. 33-9370, Amendment No. 1 (filed November 26, 1986)
4.2   Rights Agreement, dated as of April 29, 1994, between the Company and American Stock Transfer & Trust Company, as Rights Agent   Exhibit 1 to the Company’s Current Report on Form 8-K, File No. 0-15070 (filed May 2, 1994)
4.3   Amendment No. 1 to Rights Agreement, dated March 4, 2004, between the Company and American Stock Transfer & Trust Company, as Rights Agent   Exhibit 4.3 to the Company’s Annual Report on Form 10-KSB, File No. 1-15070 (filed March 31, 2006)
4.4   Warrant Agreement, dated March 12, 1997   Exhibit 4.3 to the Company’s Annual Report on Form 10-K, File No. 0-15070 (filed March 31, 1997)
4.5   Warrant Agreement, dated January 23, 2004   Exhibit 4 to the Company’s Registration Statement on Form SB-2, File No. 333-113417 (filed March 9, 2004)
4.6   Form of Warrant Agreement   Exhibit 4.1 to the Company’s Current Report on Form 8-K (filed on January 6, 2005)
4.7   Warrant Agreement, dated December 31, 2004   Exhibit 4.2 to the Company’s Current Report on Form 8-K (filed on January 6, 2005)
4.8   Form of Warrant   Exhibit 4.1 to the Company’s Current Report on Form 8-K (filed March 7, 2006)
10.1   Patent License Agreement – Exclusive, between the U.S. Public Health Service and the Company   Exhibit 10.1 to the Company’s Form 10-KSB, File No. 0-15070 (filed April 2, 2001)**

 

17


Table of Contents
10.2   Amended and Restated Directors Stock Option Plan    Exhibit 10.25 to the Company’s Annual Report on Form 10-K, File No. 0-15070 (filed March 26, 1993)
10.3   Amended and Restated 2000 Stock Option and Incentive Plan    Filed herewith
10.4   Unit Purchase Agreement dated March 12, 1997    Exhibit 10.25 to the Company’s Annual Report on Form 10-K, File No. 0-15070 (filed March 31, 1997)
10.5   Registration Rights Agreement, dated March 12, 1997    Exhibit 10.26 to the Company’s Annual Report of Form 10-K, File No. 0-15070 (filed March 31, 1997)
10.6   Lease Agreement dated April 5, 2002 between the Company and HQ Global Workplaces, Inc.    Exhibit 10.7 to the Company’s Annual Report on Form 10-KSB, File No. 0-15070 (filed March 31, 2003)
10.7   Employment Agreement    Exhibit 10.8 to the Company’s Registration Statement on Form SB-2, File No. 333-113417 (filed March 9, 2004)
10.8   Employment Agreement    Exhibit 10.9 to the Company’s Registration Statement on Form SB-2, File No. 333-113417 (filed March 9, 2004)
10.9   License Agreement    Exhibit 10.10 to the Company’s Registration Statement on Form SB-2, File No. 333-113417 (filed March 9, 2004) **
10.10   Securities Purchase Agreement    Exhibit 10.11 to the Company’s Registration Statement on Form SB-2, File No. 333-113417 (filed March 9, 2004)
10.11   Master Services Agreement    Exhibit 10.12 to the Company’s Registration Statement on Form SB-2, Amendment No. 1, File No. 333-113417 (filed April 23, 2004)
10.12   Form of Purchase Agreement    Exhibit 99.1 to the Company’s Current Report on Form 8-K (filed on January 6, 2005)
10.13   Form of Securities Purchase Agreement    Exhibit 10.1 to the Company’s Current Report on Form 8-K (filed on March 7, 2006)
31.1 & 31.2   Certifications dated August 14, 2006    Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.1 & 32.2   Certifications dated August 14, 2006    Certifications Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith)

* Except where noted, the exhibits referred to in this column have heretofore been filed with the Securities and Exchange Commission as exhibits to the documents indicated and are hereby incorporated by reference thereto. The Registration Statements referred to are Registration Statements of the Company.
** Portions of this document have been omitted pursuant to a request for confidential treatment

 

18


Table of Contents

S IGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    RegeneRx Biopharmaceuticals, Inc.
                (Registrant)
Date: August 14, 2006    

/s/ J.J. FINKELSTEIN

    J.J. Finkelstein
    President and Chief Executive Officer
   

/s/ C. NEIL LYONS

    C. Neil Lyons
    Chief Financial Officer

 

19

Exhibit 3.4

AMENDED AND RESTATED BYLAWS

OF

REGENERX BIOPHARMACEUTICALS, INC.

Adopted: July 26, 2006


AMENDED AND RESTATED BYLAWS

OF REGENERX BIOPHARMACEUTICALS, INC.

Index

 

               Page

ARTICLE I — OFFICERS

  

Section 1.1

      Registered Office    1

Section 1.2

      Other Offices    1

ARTICLE II — MEETINGS OF SHAREHOLDERS

  

Section 2.1

      Annual Meeting of Stockholders    1

Section 2.2

      Special Meetings    1

Section 2.3

      Notice of Meetings    2

Section 2.4

      Record Date    2

Section 2.5

      Voting List    3

Section 2.6

      Quorum    3

Section 2.7

      Voting of Shares    3

Section 2.8

      Proxy Voting    4

Section 2.9

      Vote Required    4

Section 2.10

      Action Without Meeting    4

ARTICLE III — DIRECTORS

  

Section 3.1

      General Powers    5

Section 3.2

      Number and Qualification    5

Section 3.3

      Term of Office    5

Section 3.4

      Nomination    5

Section 3.5

      Organization Meeting    6

Section 3.6

      Chairman of the Board of Directors    6

Section 3.7

      Regular Meetings    7

Section 3.8

      Special Meetings    7

Section 3.9

      Waiver of Notice    8

Section 3.10

      Quorum and Vote Required    8

Section 3.11

      Meeting by Telephone Conference    8

Section 3.12

      Action Without a Meeting    9

Section 3.13

      Resignations    9

Section 3.14

      Vacancies    9

Section 3.15

      Removal    9

Section 3.16

      Committees    10

Section 3.17

      Compensation    10

 

- ii -


ARTICLE IV -- OFFICERS

  

Section 4.1

        Designation    11

Section 4.2

        Election and Qualifications    11

Section 4.3

        Term of Office    11

Section 4.4

        Removal    11

Section 4.5

        Vacancies    12

Section 4.6

        Resignations    12

Section 4.7

        President    12

Section 4.8

        Vice Presidents    12

Section 4.9

        Secretary and Assistant Secretaries    13

Section 4.10

        Treasurer and Assistant Treasurer    13

Section 4.11

        Bonds    13

ARTICLE V — CERTIFICATES OF STOCK AND THEIR TRANSFER

  

Section 5.1

        Stock Certificates    14

Section 5.2

        Transfer of Shares    14

Section 5.3

        Lost, Destroyed or Stolen Certificates    15

Section 5.4

        Transfer Agent and Registrar    15

Section 5.5

        Registered Stockholders    16

ARTICLE VI — GENERAL PROVISIONS

  

Section 6.1

        Dividends    16

Section 6.2

        Seal    16

Section 6.3

        Fiscal Year    17

Section 6.4

        Notices    17

Section 6.5

        Voting Securities of Other Corporations    17

Section 6.6

        Instruments    17

Section 6.7

        Deposits    18

Section 6.8

        Reimbursement of the Corporation    18

ARTICLE VII — INDEMNIFICATION

  

Section 7.1

        Actions Other Than by or in the Right of the Corporation    18

Section 7.2

        Actions by or in the Right of the Corporation    19

Section 7.3

        Determination of Right of Indemnification    20

Section 7.4

        Good Faith Defined    20

Section 7.5

        Advances of Expenses    21

Section 7.6

        Right of Indemnitee to Indemnification Upon Application Procedure Upon Application    21

Section 7.7

        Non-Exclusivity and Survival of Indemnification    22

Section 7.8

        Insurance    23

Section 7.9

        Constituent Corporations    23

Section 7.10

        Other Enterprises, Fines, and Serving At Corporation’s Request    24

Section 7.11

        Savings Clause    24

ARTICLE VIII — INTERESTED OFFICERS OR DIRECTORS

  

ARTICLE IX — AMENDMENTS

  

 

- iii -


AMENDED AND RESTATED BYLAWS

OF REGENERX BIOPHARMACEUTICALS, INC.

ARTICLE I

OFFICES

Section 1.1 Registered Office. The registered office of RegeneRx Biopharmaceuticals, Inc. (the “Corporation”) in the State of Delaware shall be in the City of Wilmington, County of New Castle.

Section 1.2 Other Offices. The Corporation may have offices at such other places, within or without the State of Delaware, as the Board of Directors may from time to time determine or as the business of the Corporation shall require.

ARTICLE II

MEETINGS OF SHAREHOLDERS

Section 2.1 Annual Meeting of Stockholders. The annual meeting of stockholders shall be held each year at such time and place, within or without the State of Delaware, as shall be designated by the Board of Directors and stated in the notice of the meeting. At the annual meeting the stockholders shall elect the Directors of the Corporation and may transact any other business that is properly brought before the meeting.

Section 2.2 Special Meetings. Special meetings of the stockholders, for any purpose or purposes, may be called by action of the Board of Directors, by the Chairman of the Board of Directors, or by the President. Special Meetings shall be held at such place and time as shall be stated in the notice of the meeting. The business transacted at a special meeting shall be confined to matters stated in the notice of the meeting.


Section 2.3 Notice of Meetings. Unless otherwise provided by law, written notice of the place, date and hour of any meeting, and in the case of a special meeting the purpose or purposes, shall be given to each stockholder entitled to vote at the meeting not less than ten (10) nor more than sixty (60) days prior to the date of the meeting in the manner prescribed by Section 6.4 of these Bylaws. If a meeting is adjourned to another place or another date, not in excess of 30 days following the date of the meeting at which the adjournment is taken, no notice need be given of the adjourned meeting if the time and place are announced at the meeting at which the adjournment is taken, unless a new record date is fixed for the adjourned meeting. An affidavit of the mailing or other means of giving notice of any stockholder meeting shall be executed by the Secretary, Assistant Secretary or any transfer agent of the Corporation giving the notice. Such affidavit shall be filed and maintained in the minute book of the Corporation.

Section 2.4 Record Date. For the purpose of determining the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or distribution or allotment of any right, or entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date which shall not be less than ten (10) days, nor more than sixty (60) days, before the date of such meeting, nor more than sixty (60) days prior to any other action or event. When a determination of stockholders of record entitled to notice of or to vote at any meeting of stockholders has been made as provided in this Section 2.4, such determination shall apply to any adjournment thereof, unless the Board of Directors fixes a new record date under this Section 2.4 for the adjourned meeting.

 

- 2 -


Section 2.5 Voting List. The Secretary of the Corporation, or such transfer agent as may be designated by the Board of Directors, shall make and certify a complete list of the stockholders entitled to vote at any meeting of stockholders or any adjournment thereof, arranged in alphabetical order and showing the address of the stockholder and the number of registered shares held. Such list shall be open for inspection by any stockholder for any purpose germane to the meeting for a period of 10 days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list also shall be produced and kept at the place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present.

Section 2.6 Quorum. Unless otherwise required by statute or the Certificate of Incorporation, the holders of a majority of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. If at any meeting of the stockholders a quorum is not present or represented, the stockholders entitled to vote, present in person or represented by proxy, shall have the power to adjourn the meeting, from time to time, without notice other than announcement at the meeting until a quorum shall be present or represented. At such adjourned meeting any business may be transacted which might have been transacted at the meeting as originally notified. If an adjournment is for more than thirty days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.

Section 2.7 Voting of Shares. Except as otherwise provided by the Certificate of Incorporation or these Bylaws, each stockholder, present in person or represented by proxy, at any meeting shall have, on each matter on which such stockholder is entitled to vote, one vote for each outstanding share of stock having voting power registered in his name on the books of the Corporation.

 

- 3 -


Section 2.8 Proxy Voting. At any meeting of the stockholders, every stockholder having the right to vote shall be entitled to vote in person, or by proxy appointed by an instrument in writing subscribed by such stockholder and bearing a date not more than three (3) years prior to said meeting, unless said instrument provides for a longer period. The presence at any meeting of any stockholder who has given a proxy shall not revoke such proxy, unless the stockholder shall file written notice of such revocation with the secretary of the meeting prior to the voting of such proxy.

Section 2.9 Vote Required. Directors shall be elected by a plurality of the votes cast by the holders of shares present in person or represented by proxy and entitled to vote in the election. Whenever any action, other than the election of Directors, is to be taken by vote of the stockholders, it shall, except as otherwise required by statute, the Certificate of Incorporation or these Bylaws, be authorized by a majority of the votes cast by the holders of shares present in person or represented by proxy and entitled to vote thereon.

Section 2.10 Action Without Meeting. Unless otherwise provided in the Certificate of Incorporation, any action that may or is required to be taken at any annual or special meeting of stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having in the aggregate not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Prompt notice of the taking of corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing.

 

- 4 -


ARTICLE III

DIRECTORS

Section 3.1 General Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. The Board of Directors may exercise all powers, rights and privileges of the Corporation as are not by law, the Certificate of Incorporation or these Bylaws required to be exercised by the stockholders.

Section 3.2 Number and Qualification. The entire Board of Directors (the “entire Board of Directors” as used in these Bylaws shall mean the total number of Directors which the Corporation would have if there were no vacancies) shall consist of not less than 3 nor more than 7 Directors, the exact number within such minimum and maximum limits to be fixed and determined from time to time by resolution of a majority of the entire Board of Directors. Directors need not be stockholders.

Section 3.3 Term of Office. Each Director shall be elected for a one year term and shall continue to hold office until his successor is elected and qualified, or until his earlier resignation, removal or death, except that a Director elected to fill an uncompleted term shall continue to hold office until the expiration of such term and until his successor is elected and qualified, or until his earlier resignation, removal or death.

Section 3.4 Nomination. Nominations for the election of Directors may be made by the Board of Directors, any nominating committee thereof, or by any stockholder entitled to vote

 

- 5 -


for the election of Directors. Such nominations shall be made by notice, in writing, delivered or mailed by first-class United States mail, postage prepaid, to the Secretary not less than fourteen (14) days, nor more than fifty (50) days, prior to any meeting of the stockholders called for the election of Directors, except that if notice of the meeting is given to stockholders less than twenty-one (21) days in advance of the meeting, such written notice shall be delivered or mailed, as prescribed, to the Secretary not later than the close of the seventh day following the day on which notice of the meeting was mailed to stockholders. Each such notice shall set forth with respect to each nominee (i) name, age, business address and, if known, residence address, (ii) principal occupation or employment, and (iii) the number of shares of stock of the corporation beneficially owned. The chairman of the meeting may, if the facts warrant, determine and declare to the meeting that a nomination was not made in accordance with the foregoing procedure, and upon such a determination and declaration, the defective nomination shall be disregarded.

Section 3.5 Organization Meeting. The Secretary, upon receiving the results of the election of Directors at each annual meeting of stockholders, shall notify the Directors of their election and of the time at which they are required to meet at the principal office of the Corporation or such other place as the Board of Directors may designate, for the purpose of organizing the new Board of Directors, electing and appointing officers of the Corporation for the succeeding year, and considering any other business that properly is brought before the meeting. Such meeting shall be held on the day of the election or as soon thereafter as practicable.

Section 3.6 Chairman of the Board of Directors. The Chairman of the Board of Directors shall be elected by the directors from among the Directors, and shall preside over all

 

- 6 -


meetings of the stockholders and of Board of Directors. If authorized by the Board of Directors, the Chairman of the Board of Directors shall possess the same power as the President to sign all contracts, certificates and other instruments of the Corporation which may be authorized by the Board of Directors. The chairman of the Board of Directors shall perform such other duties and may exercise such other powers as from time to time may be assigned to him by the Board of Directors. The Board of Directors also may elect a Vice-Chairman of the Board of Directors from among its members. In the absence of the Chairman of the Board of Directors and, the President, if a Director, the Vice-chairman of the Board of Directors shall preside over meetings of the stockholders and of the Board of Directors and shall perform such other duties as from time to time may be assigned to him by the Board of Directors, but shall have no authority to exercise any executive powers on behalf of the Corporation.

Section 3.7 Regular Meetings. Regular meetings of the Board of Directors shall be held at such times and places, either within or without the State of Delaware, as shall from time to time be determined by resolution of the Board of Directors. No notice shall be required for a regular meeting if the meeting is held at the time and place fixed by the Board of Directors.

Section 3.8 Special Meetings. Special meetings of the Board of Directors may be called at any time by the Chairman of the Board of Directors or by the President, or upon the written request of Directors sufficient in number to constitute a quorum. Special meetings of any committee may be called by the chairman of the committee, or a sufficient number of committee members to constitute a quorum. Notice of each such special meeting shall be delivered personally, or by telephone, telegraph, cable, radio or wireless, at least twenty-four (24) hours prior to the time at which the meeting is to be held. Such notice shall state the place, date and time of the meeting and the purpose or purposes for which it is called, and shall be given in the manner prescribed by Section 6.4 of these Bylaws.

 

- 7 -


Section 3.9 Waiver of Notice. A written waiver of notice signed by a Director entitled to notice of any regular or special meeting of the Board of Directors, or a committee thereof, whether before or after the time stated therein, shall be deemed the equivalent of notice. Attendance of the Director at the meeting shall constitute a waiver of notice.

Section 3.10 Quorum and Vote Required. At all meetings of the Board of Directors, a majority of the entire Board of Directors shall constitute a quorum for the transaction of business, except that when vacancies prevent such a majority, the majority of the Directors then in office shall constitute a quorum, provided that such majority shall constitute at least one-third (1/3) of the entire Board of Directors. The action of a majority of the Directors present at any meeting at which a quorum is present shall be the action of the Board of Directors, unless the concurrence of a greater proportion is required for such action by statute, the Certificate of Incorporation or by these Bylaws. If a quorum shall not be present at any meeting of Directors, the Directors present may, by a majority vote, adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present.

Section 3.11 Meeting by Telephone Conference. Members of the Board of Directors may participate in a meeting of the Board, or any committee thereof, by means of a conference telephone or similar communications equipment if all persons participating in the meeting can hear and speak to each other at the same time. Participation in a meeting by these means constitutes presence in person at the meeting.

 

- 8 -


Section 3.12 Action Without a Meeting. Any action required or permitted to be taken at any meeting of the Board of Directors, or any committee thereof, may be taken without a meeting if all members of the Board of Directors, or committee thereof, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board of Directors or committee.

Section 3.13 Resignations. Any Director may resign at any time by giving written notice to the Board of Directors. The resignation of any Director shall take effect upon receipt of notice thereof or at such later time as shall be specified in such notice. Unless otherwise specified in the notice of resignation the acceptance of such resignation shall not be necessary to make it effective.

Section 3.14 Vacancies. Any vacancy on the Board of Directors caused by reason of an increase in the number of authorized Directors or by resignation, removal, or death may be filled by the vote of a majority of the Directors then in office, although less than a quorum, or by a sole remaining Director, or by the stockholders at a special meeting called for such purpose. Any Director so elected shall hold office until the next annual election of Directors and until his successor is elected and qualified, or until his earlier resignation, removal, or death. When one or more Directors shall resign from the Board of Directors, effective at a future date, a majority of the Directors then in office, including those that have resigned, shall have the power to fill such vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each such Director shall hold office as provided in this Section 3.13.

Section 3.15 Removal. One or more or all the Directors of the Corporation may be removed, with or without cause, by the stockholders by the affirmative vote of the majority of the votes cast by the holders of shares entitled to vote for the election of Directors at a special meeting of the stockholders expressly called for such purpose.

 

- 9 -


Section 3.16 Committees. The Board of Directors may, by resolution adopted by a majority of the entire Board of Directors, designate one or more committees, each committee to consist of two (2) or more of the Directors, which, to the extent provided in said resolution or resolutions, shall have and may exercise the powers of the Board of Directors in the management of the business and affairs of the Corporation, and may have power to authorize the seal of the Corporation to be affixed to all papers which may require it. No such committee, however, shall have the power or authority to amend the Corporation’s Certificate of Incorporation, to adopt an agreement of merger or consolidation, to recommend to the stockholders the sale, lease or exchange of all or substantially all of the Corporation’s property and assets, to recommend to the stockholders a dissolution of the Corporation or a revocation of a dissolution, or to amend the Bylaws of the Corporation. Unless a resolution of the Board of Directors or the Corporation’s Certificate of Incorporation expressly so provides, no such committee shall have the power or authority to declare a dividend or to authorize the issuance of common or preferred stock. Such committee or committees shall have such name or names as may be determined from time to time by resolution adopted by the Board of Directors. The committees shall keep regular minutes of their proceedings and report to the Board of Directors when required.

Section 3.17 Compensation. Compensation of non-employee directors for service on the board of directors and on any committees thereof, shall be set by resolution of the board. Employee directors shall not receive compensation for service on the board of directors.

 

- 10 -


ARTICLE IV

OFFICERS

Section 4.1 Designation. The officers of the Corporation shall consist of a President, a Secretary, a Treasurer, and if deemed necessary, expedient or desirable by the Board of Directors, one or more Executive Vice Presidents, Senior Vice Presidents or Vice Presidents and such other officers with such titles as the Board of Directors by resolution shall designate. Any number of such offices may be held by the same person, except that no person simultaneously may hold the offices of President and Secretary.

Section 4.2 Election and Qualifications. The officers of the Corporation shall be elected annually by the Board of Directors at its first meeting following the annual meeting of stockholders, or in the case of officers other than the President, Secretary and Treasurer, may be appointed by the President, at such times and on such terms as the President may determine. The election or appointment of an officer shall not of itself create any contract right.

Section 4.3 Term of Office. Each officer of the Corporation elected by the Board of Directors shall hold office until the next annual meeting of the Board of Directors following his election and until his successor is elected and qualified, or until his earlier resignation, removal or death.

Section 4.4 Removal. Any officer may be removed, with or without cause, at any time by the affirmative vote of the entire Board of Directors, or in the case of officers other than the President, Secretary and Treasurer, by the President. The removal of an officer without cause shall be without prejudice to his contract rights, if any.

 

- 11 -


Section 4.5 Vacancies. Any vacancy occurring in the office of President, Secretary or Treasurer shall be filled promptly by the Board of Directors.

Section 4.6 Resignations. Any officer may resign at any time by giving written notice to the Board of Directors. The resignation of any officer shall take effect upon receipt of notice thereof or at such later time as shall be specified in such notice. Unless otherwise specified in the notice of resignation, the acceptance of such resignation shall not be necessary to make it effective. Any such resignation shall be without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party.

Section 4.7 President. The President shall be the Chief Executive Officer of the Corporation. He shall be responsible for the general supervision, direction and management of the business of the Corporation, and shall see that all orders and resolutions of the Board of Directors are carried into effect. In the absence of the Chairman of the Board of Directors, the President, if a Director, shall preside at all meetings of the stockholders and of the Board of Directors. The President shall be an ex-officio member of all standing committees of the Corporation. He shall execute bonds, mortgages, contracts or other instruments of the Corporation requiring a seal, under the seal of the Corporation, except where required or permitted by law to be otherwise signed and executed, and except where the signing and execution thereof shall be expressly delegated by the Board of Directors to some other officer or agent of the Corporation.

Section 4.8 Vice Presidents. The Vice Presidents, including any Senior Vice President or Executive Vice President, shall have such powers and perform such duties as from time to time may be prescribed for them respectively by the Board of Directors or the President.

 

- 12 -


Section 4.9 Secretary and Assistant Secretaries. The Secretary shall attend all sessions of the Board of Directors and all meetings of the stockholders and record all votes and the minutes of all proceedings in a book to be kept for that purpose, and shall perform like duties for any standing committee of the Board of Directors when required. The Secretary shall give, or cause to be given, notice of all meetings of the stockholders and of special or, when required, regular meetings of the Board of Directors. He shall keep in safe custody the seal of the Corporation and, when authorized by the Board of Directors, affix the same to any instrument requiring it and, when so affixed, it shall be attested by his signature. In the absence or disability of the Secretary, the Assistant Secretary shall perform the duties and exercise the powers of the Secretary, and shall perform such other duties as the Board of Directors shall prescribe.

Section 4.10 Treasurer and Assistant Treasurer. The Treasurer shall have the custody of the corporate funds and securities and shall keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation and shall deposit all moneys and other valuable effects in the name and to the credit of the Corporation in such depositories as may be designated by the Board of Directors. The Treasurer shall disburse the funds of the Corporation as may be ordered by the Board of Directors, taking proper vouchers for such disbursements, and shall render to the President and to the Board of Directors at its regular meeting, or whenever the Board of Directors requires, an account of all his transactions as Treasurer and of the financial condition of the Corporation. In the absence or disability of the Treasurer, the Assistant Treasurer shall perform the duties and exercise the powers of the Treasurer, and shall perform such other duties as the Board of Directors shall prescribe.

Section 4.11 Bonds. If required by the Board of Directors, the Treasurer and any Assistant Treasurers or any other officer or agent of the Corporation shall give the Corporation a

 

- 13 -


bond in such sum and with such surety or sureties as shall be satisfactory to the Board of Directors for the faithful performance of the duties of his office and for the restoration to the Corporation, in the case of his death, resignation, retirement or removal from office, of all books, papers, vouchers, money and other property of whatever kind in his possession or under his control belonging to the Corporation. The Corporation shall pay the premium cost of such bonds.

ARTICLE V

CERTIFICATES OF STOCK AND THEIR TRANSFER

Section 5.1 Stock Certificates. Certificates representing shares of stock of the Corporation shall be in such form, consistent with all applicable provisions of law, as shall be approved by the Board of Directors. All certificates shall be signed in the name of the Corporation by the Chairman of the Board of Directors, the President or a Vice President and by the Treasurer or an Assistant Treasurer or the Secretary or an Assistant Secretary, and may be sealed with the seal of the Corporation or facsimile thereof. If a certificate is countersigned (1) by a transfer agent other than the Corporation or its employee, or (2) by a registrar other than the Corporation or its employee, any signature of an officer of the Corporation may be facsimile. If any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon such certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer, transfer agent or registrar at the date of its issue.

Section 5.2 Transfer of Shares. Upon payment of all taxes thereon and upon presentment to the Corporation or its transfer agent for cancellation of the certificate or certificates for the Corporation’s shares (except as provided in Section 5.3 in the case of lost, destroyed or stolen certificates) properly endorsed by the registered holder thereof or

 

- 14 -


accompanied by proper evidence of succession, assignment or authority to transfer, together with such reasonable assurance as the Corporation or its transfer agent may require that the said endorsement is genuine and effective, the Corporation or the transfer agent shall issue a new certificate to the person entitled thereto and shall cancel the old certificate and record the transaction on its books.

Section 5.3 Lost, Destroyed or Stolen Certificates. The Board of Directors may direct a new certificate or certificates to be issued in the place of any certificate or certificates issued by the Corporation alleged to have been lost, stolen or destroyed, upon making of an affidavit of that fact by the person claiming the certificate to be lost, stolen or destroyed. When authorizing the issuance of a replacement certificate or certificates, the Board of Directors in its discretion may impose such terms and conditions as it deems appropriate, including provision for indemnification of the Corporation secured by the bond or other adequate security sufficient to protect against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of the certificate or the issuance of a replacement certificate.

Section 5.4 Transfer Agent and Registrar. The Corporation may itself, at the discretion of the Board of Directors, act as its own transfer agent or registrar in such a manner as the Board of Directors shall direct. The Corporation shall, if and whenever the Board of Directors shall so determine, maintain one or more transfer offices or agencies, each in charge of a transfer agent designated by the Board of Directors, where the shares of the stock of the Corporation shall be directly transferable, and also one or more registry offices, each in charge of a registrar designated by the Board, where such shares of stock shall be registered. If a transfer agent or registrar is appointed by the Board of Directors, no certificate for shares of stock of the Corporation in respect of which a transfer agent and registrar shall have been designated shall be

 

- 15 -


valid unless countersigned by such transfer agent or registered by such registrar. The Board may also make such additional rules and regulations as it may deem expedient concerning the issue, transfer and registration of certificates for shares of the stock of the Corporation.

Section 5.5 Registered Stockholders. The Corporation shall be entitled to treat the record holder of any shares of the Corporation as the owner thereof for all purposes, including all rights deriving from such shares, and shall not be bound to recognize any equitable or other claim to, or interest in, such shares or rights deriving from such shares, on the part of any other person, including any purchaser, assignee or transferee of such shares or rights deriving from such shares, unless and until such purchaser, assignee or transferee or other person becomes the record holder of such shares, whether or not the Corporation shall have either actual or constructive notice of the interest of such purchaser, assignee or other person, except as otherwise may be provided by law.

ARTICLE VI

GENERAL PROVISIONS

Section 6.1 Dividends. Dividends upon the capital stock of the corporation, subject to the provisions of the Certificate of Incorporation, if any, may be declared and paid out of funds legally available therefore by the Board of Directors at any regular or special meeting, pursuant, to law. Dividends may be paid in cash, in property or in shares of the capital stock, subject to the provisions of the Certificate of Incorporation.

Section 6.2 Seal. The Corporation shall have a corporate seal in such form as the Board of Directors shall by resolution from time to time prescribe. The seal may be used by causing it or a facsimile thereof to be impressed, affixed or in any manner reproduced.

 

- 16 -


Section 6.3 Fiscal Year. The fiscal year of the Corporation shall end on December 31 of each year, unless otherwise designated by the Board of Directors.

Section 6.4 Notices. Any notice required by or permitted to be given by the Certificate of Incorporation, these Bylaws or otherwise shall be deemed to have been given in person if delivered in person to the person to whom such notice is addressed, shall be deemed to have been given by mail at the time it shall have been deposited in the United States mail, enclosed in a postage prepaid envelope, and shall be deemed to have been given by telegraph or cable when delivered for prepaid transmission into the custody of the messenger, with such postage prepaid envelope or such telegraph or cable message being addressed to such person at his last address as it appears on the records of the Corporation. Whenever by any provision of the Certificate of Incorporation, these Bylaws or otherwise, any notice is required or permitted to be given any specified number of days before any meeting or event, the day on which such notice was given shall be excluded, but the day of such meeting or other event shall be included, in determining whether or not notice has been given in proper time.

Section 6.5 Voting Securities of Other Corporations. The President, or such other officers of the Corporation as the Board of Directors shall designate, shall have authority to vote on behalf of the Corporation securities of another corporation which are owned or held by the Corporation, and may attend meetings of the stockholders and deliver proxies for such purpose.

Section 6.6 Instruments. All checks, drafts, notes and other obligations of the Corporation for payment of money shall be signed by such officer or officers or such other person or persons as the Board of Directors may from time to time designate.

 

- 17 -


Section 6.7 Deposits. All funds of the Corporation not otherwise employed shall be deposited from time to time to the credit of the Corporation or otherwise as the Board of Directors, the President or the Treasurer shall direct, in such banks, trust companies or other depositories as the Board of Directors may select, or as may be selected by any officer or officers or agent or agents of the Corporation as the Board of Directors may from time to time designate. For the purpose of deposit and collection for the account of the Corporation, checks, drafts and other orders for the payment of money which are payable to the order of the Corporation may be endorsed, assigned and delivered by any officer of the Corporation.

Section 6.8 Reimbursement of the Corporation. Any payments made to an officer of the Corporation, including any salary, commission, bonus, interest, rent or entertainment expense incurred by him, which shall be disallowed in whole or in part as a deductible expense by the Internal Revenue Service, shall, upon request by the Corporation, be reimbursed by such officer to the Corporation to the full extent of such disallowance. In lieu of payment by the officer, subject to the determination of the Board of Directors, proportionate amounts may be withheld from his future compensation payments until the amount owed to the Corporation has been discharged.

ARTICLE VII

INDEMNIFICATION

Section 7.1 Actions Other Than by or in the Right of the Corporation. Subject to Section 7.3 hereof, the Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that he is or was a Director, officer, employee or agent of

 

- 18 -


the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to hereinafter as an “Indemnitee”), against expenses (including attorneys’ fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit, or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, that such person had reasonable cause to believe that his conduct was unlawful.

Section 7.2 Actions by or in the Right of the Corporation. Subject to Section 7.3 hereof, the Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that he is or was an Indemnitee (as defined above) against expenses (including attorneys fees) actually and reasonably incurred by him in connection with the defense or settlement of such action or suit if he acted in good faith and in a manner he reasonably believed to be in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Corporation; except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon

 

- 19 -


application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

Section 7.3 Determination of Right of Indemnification. Any indemnification under this Article 8 (unless ordered by a court) shall be made by the Corporation only as authorized in the specific case upon a determination that indemnification of the Indemnitee is proper in the circumstances because he has met the applicable standard of conduct set forth in Section 7.1 or Section 7.2 hereof, or in defense of any claim, issue or matter therein, he shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by him in connection therewith, without the necessity of authorization in the specific case.

Section 7.4 Good Faith Defined. For purposes of any determination under Section 7.3 hereof, a person shall be deemed to have acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Corporation, or, with respect to any criminal action or proceeding, to have had no reasonable cause to believe his conduct was unlawful, if his action is based on the records or books of account of the Corporation or another enterprise, or on information supplied to him by the officers of the Corporation or another enterprise in the course of their duties, or on the advice of legal counsel for the Corporation or another enterprise or on information or records given or reports made to the Corporation or another enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Corporation or another enterprise. The term “another enterprise” as used in this Section 8.4 shall mean any other corporation or any partnership, joint venture, trust or other enterprise of which such person is or was serving at the request of the corporation as a director, officer, employee or agent. The provisions of this Section 7.4 shall not

 

- 20 -


be deemed to be exclusive or to limit in any way the circumstances in which a person may be deemed to have met the applicable standard of conduct set forth in Section 7.1 or Section 7.2 hereof, as the case may be.

Section 7.5 Advances of Expenses. Except as limited by Section 7.6 hereof, expenses (including attorneys’ fees) incurred by an Indemnitee in defending or investigating a threatened or pending action, suit or proceeding shall be paid by the Corporation in advance of the final disposition of such action, suit or proceeding if the Indemnitee shall undertake to repay such amount in the event that it is ultimately determined, as provided herein, that such person is not entitled to be indemnified by the Corporation. Notwithstanding the foregoing, no advance shall be made by the Corporation if a determination is reasonably and promptly made by the Board of Directors by a majority vote of a quorum of disinterested directors, or if such a quorum is not obtainable or, even if obtainable, a quorum of disinterested directors so directs, by independent legal counsel in a written opinion, that, based upon the facts known to the Board or counsel at the time such determination is made, such person did not meet the applicable standard of conduct set forth in Section 7.1 or Section 7.2 hereof, as the case may be.

Section 7.6 Right of Indemnitee to Indemnification Upon Application; Procedure Upon Application. Any indemnification or advancement of expenses under this Article 7 shall be made promptly, and in any event within ninety (90) days, upon the written request of the Indemnitee, unless a determination is reasonably and promptly made pursuant to Section 7.3 or Section 7.5 hereof, as the case may be, that such Indemnitee has not met the applicable standard of conduct set forth in Section 7.1 or Section 7.2 hereof, as the case may be. The right to indemnification or advancement of expenses under this Article 7 shall be enforceable by the Indemnitee in any court of competent jurisdiction if the Board of Directors or independent legal

 

- 21 -


counsel denies, in whole or in part, the Indemnitee’s request for indemnification or advancement of expenses or if no disposition of such request is made within ninety (90) days. The basis of indemnification or advancement of expenses by a court shall be a determination by such court that indemnification or advancement of expenses of the Indemnitee is proper in the circumstances because he has met the applicable standard of conduct set forth in Section 7.1 or Section 7 .2 hereof, as the case may be. Notice of any application to a court by an Indemnitee under this Section 7.6 shall be given to the Corporation promptly upon the filing of such application. The Indemnitee’s expenses actually and reasonably incurred in connection with successfully establishing his right to indemnification or advancement of expenses, in whole or in part, in any such action shall also be indemnified by the Corporation.

Section 7.7 Non-Exclusivity and Survival of Indemnification. The indemnification and advancement of expenses provided by this Article 7 shall not be deemed exclusive of any other rights to which an Indemnitee seeking indemnification or advancement of expenses may be entitled under any law (common or statutory), bylaw, agreement, contract, vote of stockholders or disinterested Directors or pursuant to the direction (howsoever embodied) of any court of competent jurisdiction or otherwise, both as to action in his official capacity and as to action in another capacity while holding such office or while employed by the Corporation, it being the policy of the Corporation that indemnification of Indemnitees shall be made to the fullest extent permitted by law. The provisions of this Article 8 shall not be deemed to preclude the indemnification of any person who is not an Indemnitee but whom the Corporation has the power or obligation to indemnify under the provisions of the Delaware General Corporation Law, or otherwise. The indemnification and advancement of expenses provided by, or granted pursuant to, this Article 7 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be an Indemnitee and shall inure to the benefit of the heirs,

 

- 22 -


executors and administrators of such person. All rights to indemnification and advancement of expenses under this Article 7 shall be deemed to be provided by a contract between the Corporation and each Indemnitee who serves or served in such capacity at any time while this Article 7 and other relevant provisions of the General Corporation Law and other applicable law, if any, are in effect, and any repeal or modification thereof shall not affect any rights or obligations then existing with respect to any state of facts then or theretofore existing or any action, suit or proceeding theretofore or thereafter brought or threatened based in whole or in part upon any such state of facts.

Section 7.8 Insurance. The Corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the Corporation would have the power or the obligation to indemnify him against such liability under the provisions of this Article 7.

Section 7.9 Constituent Corporations. For purpose of this Article 7, references to “the Corporation” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Article 7 with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had continued.

 

- 23 -


Section 7.10 Other Enterprises, Fines and Serving At Corporation’s Request. For purposes of this Article 7, references to “other enterprises” shall include employee benefit plans; references to “fines” shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references to “serving at the request of the Corporation” shall include any services as a director, officer, employee, or trustee of the Corporation which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the interest of the participants and beneficiaries of any employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Corporation” as referred to in this Article 7.

Section 7.11 Savings Clause. If this Article 7 or any portion thereof shall be invalidated on any ground by a court of competent jurisdiction, then the Corporation shall nevertheless indemnify each Indemnitee as to expenses (including attorneys’ fees), judgments, fines, and amounts paid in settlement with respect to any action, suit or proceeding, whether civil, criminal or administrative, and whether internal or external, including a grand jury proceeding and an action or suit brought by or in the right of the Corporation, to the fullest extent permitted by any applicable portion of this Article 7 that shall not have been invalidated, or by any other applicable law.

 

- 24 -


ARTICLE VIII

INTERESTED OFFICERS OR DIRECTORS

No contract or transaction between this Corporation and one or more of its Directors or officers, or between this Corporation and any other corporation, partnership, association, or other organization in which one or more of its Directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the Director or officer is present at or participates in the meeting of the Board of Directors or a committee thereof which authorizes the contract or transaction, or solely because his or their votes are counted for such purpose, if:

(a) The material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the Board of Directors or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested Directors, even though the disinterested Directors represent less than a quorum; or

(b) The material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or

(c) The contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board of Directors, a committee thereof, or the stockholders.

 

- 25 -


Common or interested Directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee which authorized the contract or transaction.

ARTICLE IX

AMENDMENTS

These Bylaws may be altered or repealed, subject to any provision which might pertain in the Certificate of Incorporation, by majority vote of the stock outstanding at the annual meeting or at any special meeting of stockholders or by resolution adopted by a majority vote of the Board of Directors at any regular or special meeting of the Board of Directors.

 

- 26 -

Exhibit 10.3

REGENERX BIOPHARMACEUTICALS, INC.

Amended and Restated 2000 Stock Option and Incentive Plan

1. Plan Purpose . The purpose of the Plan is to promote the long-term interests of the Corporation and its stockholders by providing a means for attracting and retaining directors, officers, employees, Consultants and Advisors of the Corporation and its Affiliates and to motivate such persons to exert their best efforts on behalf of the Corporation and its Affiliates.

2. Definitions . The following definitions are applicable to the Plan:

“Advisor” — means an advisor retained by the Corporation or an Affiliate who: (i) is a natural person; and (ii) provides bona fide services to the Corporation or an Affiliate, which services are not in connection with the offer or sale of securities in a capital-raising transaction, and do not directly or indirectly promote or maintain a market for the Corporation’s securities.

“Affiliate” — means any “parent corporation” or “subsidiary corporation” of the Corporation, as such terms are defined in Sections 424(e) and (f), respectively, of the Code.

“Board” — means the board of directors of the Corporation.

“Cause” — means Termination of Service by reason of personal dishonesty, incompetence, willful misconduct, breach of fiduciary duty involving personal profit, intentional failure to perform stated duties or gross negligence.

“Code” — means the Internal Revenue Code of 1986, as amended.

“Committee” — means the Committee referred to in Section 3 hereof.

“Consultant” — means a consultant retained by the Corporation or a Affiliate who: (i) is a natural person; and (ii) provides bona fide services to the Corporation or an Affiliate, which services are not in connection with the offer or sale of securities in a capital-raising transaction, and do not directly or indirectly promote or maintain a market for the Corporation’s securities.

“Corporation” — means RegeneRx Biopharmaceuticals, Inc., a Delaware corporation, and any successor thereto.

“Disability” — has the meaning assigned to such term in Section 22(e)(3) of the Code, or any successor provision.

“Employee” — means any person who is employed by the Corporation, and whose wages are reported on a Form W-2. The Corporation’s classification as to who is an Employee shall be determinative for purposes of an individual’s eligibility under the Plan.

“Incentive Stock Option” — means an option to purchase Shares granted by the Committee which is intended to qualify as an incentive stock option under Section 422(b) of the Code.

 

1


Unless otherwise set forth in the Option Agreement, any Option which does not qualify as an Incentive Stock Option for any reason shall be deemed ab initio to be a Non-Qualified Stock Option.

“Market Value” — means, on the date in question (or, if the date in question is not a trading day, on the last trading day preceding the date in question), the per share closing price of the Shares on the principal securities exchange on which the Shares are listed (if the Shares are so listed), or on the Nasdaq Stock Market (if the Shares are listed on the Nasdaq Stock Market), or, if not listed on a securities exchange or the Nasdaq Stock Market, the average of the per share closing bid prices of the Shares as reported on the OTC Bulletin Board, or, if such bid prices are not reported on the OTC Bulletin Board, as reported by any nationally recognized quotation service selected by the Committee, in each such case averaged over a period of the twenty (20) trading days preceding the date in question, or, if no such price information is reported, the fair market value on such date of a Share as the Committee shall determine.

“Non-Qualified Stock Option” — means an option to purchase Shares granted by the Committee which does not qualify, for any reason, as an Incentive Stock Option.

“Option” — means an Incentive Stock Option or a Non-Qualified Stock Option.

“Option Agreement” — means the agreement evidencing the grant of an Option under the Plan.

“Participant” — means any director, officer, employee, Consultant or Advisor of the Corporation or any Affiliate who is selected to receive an Option pursuant to Section 5.

“Plan” — means this RegeneRx Biopharmaceuticals, Inc. 2000 Stock Option and Incentive Plan.

“Shares” — means the shares of common stock of the Corporation.

“Termination of Service” — means cessation of service, for any reason, whether voluntary or involuntary, so that the affected individual is not either (i) an employee of the Corporation or any Affiliate for purposes of an Incentive Stock Option, or (ii) a director, officer, employee, Consultant or Advisor of the Corporation or any Affiliate for purposes of a Non-Qualified Stock Option.

3. Administration .

(a) The Plan shall be administered by a Committee consisting of either (i) each member of the Board, or (ii) two or more members of the Board appointed by the Board, each of whom (A) shall be an “outside director,” as defined under Section 162(m) of the Code and the Treasury regulations thereunder, and (B) shall be a “non-employee director,” as defined under Rule 16b-3 under the Securities Exchange Act of 1934, as amended, or any similar or successor provision. Except as limited by the express provisions of the Plan or by resolutions adopted by the Board, the Committee shall have sole and complete authority and discretion to (i) select

 

2


Participants and grant Options; (ii) determine the number of Shares to be subject to types of Options generally, as well as to individual Options granted under the Plan; (iii) determine the terms and conditions upon which Options shall be granted under the Plan; (iv) prescribe the forms and terms of Option Agreements; (v) establish from time to time regulations for the administration of the Plan; and (vi) interpret the Plan and make all determinations deemed necessary or advisable for the administration of the Plan.

A majority of the Committee shall constitute a quorum, and the acts of a majority of the members present at any meeting at which a quorum is present, or acts approved in writing by a majority of the Committee without a meeting, shall be acts of the Committee.

(b) Limitation on Liability. No Committee member shall be liable for any action or determination made in good faith with respect to the Plan. To the maximum extent allowed by law and the Corporation’s bylaws, the Committee shall be indemnified by the Corporation in respect of all their activities under the Plan.

4. Shares Subject to Plan .

(a) Subject to adjustment by the operation of Section 6, the maximum number of Shares with respect to which Options may be granted under the Plan is four million two hundred thousand (4,200,000), plus (i) the number of Shares repurchased by the Corporation in the open market or otherwise with an aggregate price no greater than the cash proceeds received by the Corporation from the exercise of Options granted under the Plan; plus (ii) any Shares surrendered to the Corporation in payment of the exercise price of Options granted under the Plan. The Shares with respect to which Options may be granted under the Plan may be either authorized and unissued Shares or previously issued Shares reacquired and held as treasury Shares. An Option which terminates shall not be considered to have been granted under the Plan, and new Options may be granted under the Plan with respect to the number of Shares as to which such termination has occurred.

(b) During any calendar year, no Participant may be granted Options under the Plan with respect to more than 750,000 Shares, subject to adjustment as provided in Section 6.

5. Options . The Committee is hereby authorized to grant Incentive Stock Options and Non-Qualified Stock Options to Participants with the following terms and conditions and with such additional terms and conditions not inconsistent with the provisions of the Plan and the requirements of applicable law as the Committee shall determine:

(i) Exercise Price. The exercise price per Share for an Option shall be determined by the Committee; provided, however, that such exercise price shall not be less than 100% of the Market Value of a Share on the date of grant of such Option; provided, further, that in the case of an Incentive Stock Option granted to an individual who, at the time of grant, is the beneficial owner of stock possessing more than ten percent of the total combined voting power of all classes of stock of the Corporation or any Affiliate (a “Ten Percent Owner”), such exercise price shall not be less than 110% of the Market Value of a Share on the date of grant of such Option.

 

3


(ii) Option Term. The term of each Option shall be fixed by the Committee, but shall be no greater than ten years in the case of a Non-Qualified Stock Option, ten years in the case of an Incentive Stock Option granted to a Participant who is not a Ten Percent Owner, and five years in the case of a Incentive Stock Option granted to a Participant who is a Ten Percent Owner.

(iii) Number of Shares and Time and Method of Exercise. The Committee shall determine the number of Shares underlying each Option and the time or times at which an Option may be exercised in whole or in part and the method or methods by which, and the form or forms (including, without limitation, cash, Shares, or any combination thereof, having a fair market value on the exercise date equal to the relevant exercise price) in which, payment of the exercise price with respect thereto may be made or deemed to have been made.

(iv) Incentive Stock Options . Incentive Stock Options may be granted by the Committee only to employees of the Corporation or its Affiliates. No Incentive Stock Option may be granted more than ten years after the effective date of the Plan, as set forth in Section 14. The aggregate Market Value (determined as of the time any Incentive Stock Option is granted) of the Shares with respect to which Incentive Stock Options are exercisable for the first time by a Participant in any calendar year shall not exceed $100,000. To the extent that the aggregate Market Value of such Shares exceeds $100,000, such excess shall, upon exercise, be treated as Shares received pursuant to the exercise of a Non-Qualified Stock Option. The Corporation shall designate which Shares to be received by the Participant will be treated as Incentive Stock Option stock and which Shares will be treated as Non-Qualified Stock Option stock by issuing separate share certificates and identifying them as such in the Corporation’s share transfer records.

(v) Termination of Service. Unless otherwise determined by the Committee and set forth in the Option Agreement evidencing the grant of the Option, upon Termination of Service of a Participant for any reason other than for Cause or due to death or Disability, each Option granted to the Participant, to the extent then exercisable, shall remain exercisable for the lesser of (A) three months following such Termination of Service and (B) the period of time until the expiration of the Option by its terms. Unless otherwise determined by the Committee and set forth in the Option Agreement evidencing the grant of the Option, upon Termination of Service of a Participant due to death or Disability, each Option granted to the Participant, to the extent then exercisable, shall remain exercisable for the lesser of (A) one year following such Termination of Service and (B) the period of time until the expiration of the Option by its terms. Upon Termination of Service of a Participant for Cause, each Option granted to the Participant, to the extent not previously exercised, shall immediately be forfeited.

6. Adjustments Upon Changes in Capitalization . In the event of any change in the outstanding Shares subsequent to the effective date of the Plan by reason of any reorganization, recapitalization, stock split, stock dividend, combination or exchange of shares, merger, consolidation or any change in the corporate structure or Shares of the Corporation, the maximum aggregate number and class of shares as to which Options may be granted under the Plan and the number and class of shares underlying outstanding Options granted under the Plan

 

4


(as well as the exercise price of each such outstanding Option) shall be appropriately adjusted by the Committee, whose determination shall be conclusive. Except as otherwise provided herein, any Option which is adjusted as a result of this Section 6 shall be subject to the same terms and conditions as the original Option.

7. Effect of Merger on Options . In the case of any merger, consolidation or combination of the Corporation (other than a merger, consolidation or combination in which the Corporation is the continuing corporation and which does not result in the outstanding Shares being converted into or exchanged for different securities, cash or other property, or any combination thereof), any Participant to whom an Option has been granted shall have the additional right (subject to the provisions of the Plan and any limitation applicable to such Option), thereafter and during the term of each such Option, to receive upon exercise of any such Option an amount equal to the excess of the fair market value on the date of such exercise of the securities, cash or other property, or combination thereof, receivable upon such merger, consolidation or combination in respect of a Share over the exercise price of such Option, multiplied by the number of Shares with respect to which such Option shall have been exercised. Such amount may be payable fully in cash, fully in one or more of the kind or kinds of property payable in such merger, consolidation or combination, or partly in cash and partly in one or more of such kind or kinds of property, all in the discretion of the Committee.

8. Effect of Change in Control . Each of the events specified in the following clauses (i) through (iii) of this Section 8 shall be deemed a “change in control”: (i) any third person, including a “group” as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, shall become the beneficial owner of shares of the Corporation with respect to which 50% or more of the total number of votes for the election of the Board may be cast, (ii) as a result of, or in connection with, any cash tender offer, merger or other business combination, sale of assets or contested election, or combination of the foregoing, the persons who were directors of the Corporation shall cease to constitute a majority of the Board, or (iii) the stockholders of the Corporation shall approve an agreement providing either for a transaction in which the Corporation will cease to be an independent publicly-owned corporation or for a sale or other disposition of all or substantially all the assets of the Corporation. If a tender offer or exchange offer for Shares (other than such an offer by the Corporation) is commenced, or if a change in control shall occur, unless the Committee shall have otherwise provided in the Option Agreement, all Options granted and not fully exercisable shall become exercisable in full upon the happening of such event; provided, however, that no Option which has previously been exercised or otherwise terminated shall become exercisable.

9. Assignments and Transfers . No Incentive Stock Option granted under the Plan shall be transferable other than by will or the laws of descent and distribution. A Non-Qualified Stock Option shall be transferable by will, the laws of descent and distribution, a “domestic relations order,” as defined in Section 414(p)(1)(B) of the Code, or a gift to any member of the Participant’s immediate family or to a trust for the benefit of one or more of such immediate family members. During the lifetime of an Option recipient, an Option shall be exercisable only by the Option recipient unless it has been transferred as permitted hereby, in which case it shall be exercisable only by such transferee. For the purpose of this Section 9, a Participant’s “immediate family” shall mean the Participant’s spouse, children and grandchildren.

 

5


10. Certain Rights Under the Plan . No person shall have a right to be selected as a Participant nor, having been so selected, to be selected again as a Participant, and no director, officer, employee, Consultant, Advisor or other person shall have any claim or right to be granted an Option under the Plan or under any other incentive or similar plan of the Corporation or any Affiliate. Neither the Plan nor any action taken hereunder shall be construed as giving any employee, Consultant or Advisor any right to be retained in the employ of or as a Consultant or Advisor to the Corporation or any Affiliate.

11. Delivery and Registration of Stock . The Corporation’s obligation to deliver Shares with respect to an Option shall, if the Committee so requests, be conditioned upon the receipt of a representation as to the investment intention of the Participant to whom such Shares are to be delivered, in such form as the Committee shall determine to be necessary or advisable to comply with the provisions of the Securities Act of 1933, as amended, or any other federal, state or local securities legislation. It may be provided that any representation requirement shall become inoperative upon a registration of the Shares or other action eliminating the necessity of such representation under such Securities Act or other securities legislation. The Corporation shall not be required to deliver any Shares under the Plan prior to (i) the admission of such Shares to listing on any stock exchange on which Shares may then be listed and (ii) the completion of such registration or other qualification of such Shares under any state or federal law, rule or regulation, as the Committee shall determine to be necessary or advisable.

12. Withholding, Notice of Disposition .

(a) Where a Participant or other person is entitled to receive Shares pursuant to the exercise of an Option pursuant to the Plan, the Corporation shall have the right to require the Participant or such other person to pay the Corporation the amount of any taxes which the Corporation is required to withhold with respect to such Shares, or, in lieu thereof, to retain, or sell without notice, a number of such Shares sufficient to cover the amount required to be withheld. If the Corporation retains or sells a number of Shares that a Participant otherwise would be entitled to, the fair market value of the Shares retained for such purpose shall not exceed the minimum required Federal, state and local tax withholding due upon exercise of the Option. All withholding decisions pursuant to this Section 12 shall be at the sole discretion of the Committee or the Corporation.

(b) A Participant shall immediately notify the Corporation in writing of any sale, transfer, assignment or other disposition (or action constituting a disqualifying disposition within the meaning of Section 421 of the Code) of any Shares acquired through exercise of an Incentive Stock Option, within two (2) years after the grant of such Incentive Stock Option or within one (1) year after the acquisition of such Shares, setting forth the date and manner of disposition, the number of Shares disposed of and the price at which such Shares were disposed. The Corporation shall be entitled to withhold from any compensation or other payments then or thereafter due to the Participant such amounts as may be necessary to satisfy any withholding requirements of Federal or state law or regulation and, further, to collect from the Participant any additional amounts which may be required for such purpose.

 

6


13. Amendment or Termination .

(a) The Board may amend, alter, suspend, discontinue, or terminate the Plan without the consent of shareholders or Participants, except that any such action will be subject to the approval of the Corporation’s shareholders if, when and to the extent such shareholder approval is necessary or required for purposes of any applicable federal or state law or regulation or the rules of any stock exchange or automated quotation system on which the Shares may then be listed or quoted, or if the Board, in its discretion, determines to seek such shareholder approval.

(b) The Committee may waive any conditions of or rights of the Corporation or modify or amend the terms of any outstanding Option. The Committee may not, however, amend, alter, suspend, discontinue or terminate any outstanding Option without the consent of the Participant or holder thereof, except as otherwise provided herein.

14. Effective Date and Term of Plan . The Plan shall become effective upon the later of its adoption by the Board or its approval by the shareholders of the Corporation. It shall continue in effect for a term of ten years thereafter unless sooner terminated under Section 13 hereof.

 

7

EXHIBIT 31.1

CERTIFICATION

I, J.J. Finkelstein certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of RegeneRx Biopharmaceuticals, Inc.;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) [*** Omitted pursuant to extended compliance period] for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) [***Omitted pursuant to extended compliance period]

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2006

 

/s/ J.J. FINKELSTEIN

J.J. Finkelstein
Chief Executive Officer

EXHIBIT 31.2

CERTIFICATION

I, C. Neil Lyons certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of RegeneRx Biopharmaceuticals, Inc.;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) [*** Omitted pursuant to extended compliance period] for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) [***Omitted pursuant to extended compliance period]

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2006

 

/s/ C. NEIL LYONS

C. Neil Lyons
Chief Financial Officer

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of RegeneRx (the “Company”) on Form 10-Q for the period ending June 30, 2006, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, J.J. Finkelstein, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company as of and for the periods presented in this report.

Date: August 14, 2006

 

/s/ J.J. FINKELSTEIN

Chief Executive Officer

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of RegeneRx (the “Company”) on Form 10-Q for the period ending June 30, 2006, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, C. Neil Lyons, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company as of and for the periods presented in this report.

Date: August 14, 2006

 

/s/ C. NEIL LYONS

C. Neil Lyons
Chief Financial Officer